Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma [8]

Archives of Dermatology

Volumn 142, Issue 11, 2006, Pages 1516-1517

  Perez Gala, Silvia ^a   Delgado Jimenez, Yolanda ^b   Goiriz, Rebeca ^b   Fraga, Javier ^b   Garcia Diez, Amaro ^b   Fernandez Herrera, Jesus ^b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; STEROID;

ADULT; ANAMNESIS; B CELL LYMPHOMA; CASE REPORT; CYTOKINE RELEASE; ERYTHEMA; HUMAN; HUMAN TISSUE; LETTER; MALE; PRIORITY JOURNAL; PRURITUS; RASH; SCAR; SKIN LYMPHOMA; SWELLING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CICATRIX; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LYMPHOMA, B-CELL; MALE; SKIN NEOPLASMS; SYNDROME;

EID: 33751230473     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.11.1516     Document Type: Letter

References (5)

1. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520-535.
2. Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol. 2000;136:374-378.
3. Gellrich S, Muche JM, Wilks A, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation. Br J Dermatol. 2005;153:167-173.
4. Heinzerling LM, Urbanek M, Funk JO, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti CD-20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000;89:1835-1844.
5. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52:847-853.